BR0317606A - Métodos de tratamento de distúrbios não dolorosos da bexiga urinária que usam moduladores de canal de cálcio de subunidade (alfa)2(delta) - Google Patents

Métodos de tratamento de distúrbios não dolorosos da bexiga urinária que usam moduladores de canal de cálcio de subunidade (alfa)2(delta)

Info

Publication number
BR0317606A
BR0317606A BR0317606-1A BR0317606A BR0317606A BR 0317606 A BR0317606 A BR 0317606A BR 0317606 A BR0317606 A BR 0317606A BR 0317606 A BR0317606 A BR 0317606A
Authority
BR
Brazil
Prior art keywords
subunit
calcium channel
delta
alpha
methods
Prior art date
Application number
BR0317606-1A
Other languages
English (en)
Inventor
Karl Bruce Thor
Edward C Burgard
Matthew Oliver Fraser
Original Assignee
Dynogen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dynogen Pharmaceuticals Inc filed Critical Dynogen Pharmaceuticals Inc
Publication of BR0317606A publication Critical patent/BR0317606A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Mobile Radio Communication Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

"MéTODOS DE TRATAMENTO DE DISTúRBIOS NãO DOLOROSOS DA BEXIGA URINáRIA QUE USAM MODULADORES DE CANAL DE CáLCIO DE SUBUNIDADE <244>~ 2~<sym>". é fornecido um método de tratamento de distúrbios não dolorosos da bexiga, particularmente bexiga hiperativa não dolorosa sem perda de urina. O método compreende a administração de um modulador de canal de cálcio de subunidade <244>~ 2~<sym>, que inclui análogos de gabapentina, pregabalina, GABA, análogos de aminoácidos bicíclicos ou tricíclicos fundidos de gabapentina, compostos de aminoácidos e outros compostos que interagem com a subunidade <244>~ 2~<sym> de canal de cálcio.
BR0317606-1A 2002-12-20 2003-12-19 Métodos de tratamento de distúrbios não dolorosos da bexiga urinária que usam moduladores de canal de cálcio de subunidade (alfa)2(delta) BR0317606A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US43502102P 2002-12-20 2002-12-20
US48605703P 2003-07-10 2003-07-10
US52562303P 2003-11-26 2003-11-26
PCT/US2003/040730 WO2004058168A2 (en) 2002-12-20 2003-12-19 METHODS OF TREATING NON-PAINFUL BLADDER DISORDERS USING α2δ SUBUNIT CALCIUM CHANNEL MODULATORS

Publications (1)

Publication Number Publication Date
BR0317606A true BR0317606A (pt) 2005-11-29

Family

ID=32686079

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0317606-1A BR0317606A (pt) 2002-12-20 2003-12-19 Métodos de tratamento de distúrbios não dolorosos da bexiga urinária que usam moduladores de canal de cálcio de subunidade (alfa)2(delta)

Country Status (13)

Country Link
US (5) US20040142034A1 (pt)
EP (1) EP1480631B1 (pt)
JP (1) JP2006511624A (pt)
KR (1) KR20050084445A (pt)
AT (1) ATE368456T1 (pt)
AU (2) AU2003301184A1 (pt)
BR (1) BR0317606A (pt)
CA (1) CA2510292A1 (pt)
DE (1) DE60315258T2 (pt)
ES (1) ES2288641T3 (pt)
MX (1) MXPA05006656A (pt)
PL (1) PL376949A1 (pt)
WO (1) WO2004058168A2 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040180958A1 (en) * 2002-12-13 2004-09-16 Taylor Charles Price Method of treatment
CA2509605C (en) 2002-12-13 2010-10-05 Warner-Lambert Company Llc Alpha-2-delta ligand to treat lower urinary tract symptoms
KR20050084445A (ko) * 2002-12-20 2005-08-26 다이노젠 파마세우티컬스, 인코포레이티드 α₂δ 서브유닛 칼슘 채널 모듈레이터를 이용한 무통증방광 질환의 치료방법
CN1791399A (zh) * 2003-03-21 2006-06-21 戴诺根医药品公司 用α2δ亚基钙通道调节剂和平滑肌调节剂一起治疗下泌尿道病症的方法
US20040248979A1 (en) * 2003-06-03 2004-12-09 Dynogen Pharmaceuticals, Inc. Method of treating lower urinary tract disorders
US7838029B1 (en) * 2003-07-31 2010-11-23 Watson Laboratories, Inc. Mirtazapine solid dosage forms
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
EP1670451A4 (en) 2003-09-11 2009-10-21 Xenoport Inc TREATMENT AND / OR PREVENTION OF URINARY INCONTINENCE AND PROMOTERS OF GABA ANALOGS
KR20080014056A (ko) 2005-05-20 2008-02-13 오메로스 코포레이션 시클로옥시게나제 저해제 및 칼슘채널 길항제 조성물 및이의 비뇨기과 시술시의 용도를 위한 방법
US20070010543A1 (en) * 2005-07-01 2007-01-11 Dynogen Pharmaceuticals, Inc. Compositions and methods for treating gastrointestinal hypomotility and associated disorders
KR20090092307A (ko) 2006-12-22 2009-08-31 레코르다티 아일랜드 리미티드 하요도 장애에 대한 α2δ 리간드 및 ＮＳＡＩＤｓ의 복합 치료
US9220837B2 (en) 2007-03-19 2015-12-29 Insuline Medical Ltd. Method and device for drug delivery
US8622991B2 (en) 2007-03-19 2014-01-07 Insuline Medical Ltd. Method and device for drug delivery
WO2008114223A1 (en) 2007-03-19 2008-09-25 Insuline Medical Ltd. Drug delivery device
EP2231229A1 (en) 2007-12-18 2010-09-29 Insuline Medical Ltd. Drug delivery device with sensor for closed-loop operation
CA2743027C (en) 2008-11-07 2016-04-12 Insuline Medical Ltd. Device and method for drug delivery

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US55109A (en) * 1866-05-29 Improvement in screw-wrenches
US18061A (en) * 1857-08-25 Island
US45662A (en) * 1864-12-27 Improvement in supporters for artificial legs
US32235A (en) * 1861-04-30 mccormick
US91159A (en) * 1869-06-08 Improved lifting-device for drop-presses and hammers
US5180715A (en) * 1980-11-17 1993-01-19 The Regents Of The University Of California Irrigation of internal bladder surfaces in mammals with sodium pentosanpolysulfate
US5116615A (en) * 1989-01-27 1992-05-26 Immunolytics, Inc. Method for treating benign prostatic hypertrophy
DE3928183A1 (de) * 1989-08-25 1991-02-28 Goedecke Ag Lactamfreie cyclische aminosaeuren
AU7707994A (en) * 1993-09-30 1995-04-18 Tokyo Tanabe Company Limited Indoline derivative and 5-ht3 receptor antagonist containing the same as active ingredient
US5698549A (en) * 1994-05-12 1997-12-16 Uva Patent Foundation Method of treating hyperactive voiding with calcium channel blockers
NO2005012I1 (no) * 1994-12-28 2005-06-06 Debio Rech Pharma Sa Triptorelin og farmasoytisk akseptable salter derav
US5912268A (en) * 1995-05-22 1999-06-15 Alza Corporation Dosage form and method for treating incontinence
DE19523868A1 (de) * 1995-06-30 1997-01-02 Huels Chemische Werke Ag Verfahren zur Herstellung von Cyclopropanamin
US5610136A (en) * 1996-01-30 1997-03-11 Milkhaus Laboratory, Inc. Method for treatment of benign prostatic hypertrophy
US5738873A (en) * 1996-09-27 1998-04-14 Herman Bleiweiss Pharmaceutical formulations and methods for treating patients suffering from diseases that cause muscular hypotonia
US6255526B1 (en) * 1996-12-24 2001-07-03 Teva Pharmaceutical Industries Ltd. Preparation of gabapentin
US6150396A (en) * 1997-03-07 2000-11-21 Eli Lilly And Company Methods of treating or preventing interstitial cystitis
WO1998046216A1 (fr) * 1997-04-11 1998-10-22 Nippon Shinyaku Co., Ltd. Traitements des mictions frequentes et de l'incontinence urinaire
US6329429B1 (en) * 1997-06-25 2001-12-11 Warner-Lambert Company Use of GABA analogs such as Gabapentin in the manufacture of a medicament for treating inflammatory diseases
US6066643A (en) * 1997-10-17 2000-05-23 Eli Lilly And Company Potentiation of pharmaceuticals
FR2771093B1 (fr) * 1997-11-19 2000-01-21 Synthelabo Derives d'imidazole, leur preparation et leur application en therapeutique
US6319920B1 (en) * 1998-02-27 2001-11-20 Syntex (U.S.A.) Llc 2-arylethyl-(piperidin-4-ylmethyl)amine derivatives
US6482837B1 (en) * 1998-04-24 2002-11-19 University Of Rochester Antimuscarinic compounds and methods for treatment of bladder diseases
US6316638B1 (en) * 1998-05-26 2001-11-13 Warner-Lambert Company Conformationally constrained amino acid compounds having affinity for the alpha2delta subunit of a calcium channel
IL127129A (en) * 1998-11-18 2004-06-01 Ferring Bv Method for preparation of progesterone tablets for vaginal delivery and tablets so prepared
US6329798B1 (en) * 1998-12-11 2001-12-11 Honeywell International Inc Voltage controller for minimizing the utility power provided to a local load site having a local power source
WO2000061135A1 (en) * 1999-04-08 2000-10-19 Warner-Lambert Company Method for the treatment of incontinence
AU3735000A (en) * 1999-05-05 2000-11-21 Warner-Lambert Company Modulation of substance p by gaba analogs and methods relating thereto
US20030018061A1 (en) * 2000-01-28 2003-01-23 Kohei Ogawa Novel remedies with the use of beta 3 agonist
US6531509B2 (en) * 2000-06-16 2003-03-11 Teva Pharmaceutical Industries Ltd. Stable gabapentin containing more than 20 ppm of chlorine ion
JP2003535885A (ja) * 2000-06-16 2003-12-02 テバ ファーマシューティカル インダストリーズ リミティド 制御された範囲内にｐＨを持つ安定なギャバペンチン
US7056951B2 (en) * 2000-09-26 2006-06-06 Mutual Pharmaceutical Co., Inc. Stable solid dosage forms of amino acids and processes for producing same
HN2001000224A (es) * 2000-10-19 2002-06-13 Pfizer Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
AU2002215160A1 (en) * 2000-11-30 2002-06-11 Pfizer Products Inc. Combination of gaba agonists and aldose reductase inhibitors
GB0119435D0 (en) * 2001-02-15 2001-10-03 Aventis Pharm Prod Inc Method of treating of demyelinating diseases or conditions
CA2440141A1 (en) * 2001-03-06 2002-09-12 Cellegy Pharmaceuticals, Inc. Compounds and methods for the treatment of urogenital disorders
CZ299755B6 (cs) * 2001-05-25 2008-11-12 Warner-Lambert Company Llc Kapalná farmaceutická kompozice obsahující analoggama-aminomáselné kyseliny, zpusob její prípravy a použití
DE10146275A1 (de) * 2001-09-18 2003-04-24 Gruenenthal Gmbh Kombination ausgewählter Opioide mit Muscarin-Antagonisten zur Therapie der Harninkontinenz
US6974818B2 (en) * 2002-03-01 2005-12-13 Euro-Celtique S.A. 1,2,5-thiadiazol-3-YL-piperazine therapeutic agents useful for treating pain
CA2509605C (en) * 2002-12-13 2010-10-05 Warner-Lambert Company Llc Alpha-2-delta ligand to treat lower urinary tract symptoms
KR20050084445A (ko) * 2002-12-20 2005-08-26 다이노젠 파마세우티컬스, 인코포레이티드 α₂δ 서브유닛 칼슘 채널 모듈레이터를 이용한 무통증방광 질환의 치료방법
CN1791399A (zh) * 2003-03-21 2006-06-21 戴诺根医药品公司 用α2δ亚基钙通道调节剂和平滑肌调节剂一起治疗下泌尿道病症的方法
DE602004007225T2 (de) * 2003-04-04 2008-03-06 Dynogen Pharmaceuticals Inc., Waltham Methode zur behandlung von erkrankungen der unteren harnwege
US7661614B2 (en) * 2004-09-10 2010-02-16 Fellowes Inc. Shredder throat safety system

Also Published As

Publication number Publication date
US20050228049A1 (en) 2005-10-13
DE60315258T2 (de) 2008-05-08
CA2510292A1 (en) 2004-07-15
ES2288641T3 (es) 2008-01-16
JP2006511624A (ja) 2006-04-06
WO2004058168B1 (en) 2004-11-11
EP1480631A4 (en) 2005-05-04
US20040142034A1 (en) 2004-07-22
ATE368456T1 (de) 2007-08-15
MXPA05006656A (es) 2006-02-22
US20060188575A1 (en) 2006-08-24
WO2004058168A2 (en) 2004-07-15
KR20050084445A (ko) 2005-08-26
US20090203792A1 (en) 2009-08-13
EP1480631A2 (en) 2004-12-01
US20050054725A1 (en) 2005-03-10
DE60315258D1 (de) 2007-09-13
AU2003301184A1 (en) 2004-07-22
AU2010200722A1 (en) 2010-03-18
WO2004058168A3 (en) 2004-09-02
PL376949A1 (pl) 2006-01-09
EP1480631B1 (en) 2007-08-01
AU2003301184A2 (en) 2004-07-22

Similar Documents

Publication Publication Date Title
BR0317606A (pt) Métodos de tratamento de distúrbios não dolorosos da bexiga urinária que usam moduladores de canal de cálcio de subunidade (alfa)2(delta)
BRPI0408608A (pt) uso de moduladores da subunidade (alfa)2(delta) de canal de cálcio e moduladores de músculo liso para tratamento de sintoma de um distúrbio do trato urinário inferior
IL213649A0 (en) Prodrugs of gabapentin compounds, compositions and their use in the manufacture of a medicament
BR0312785A (pt) Tratamento de desordens relacionadas a tnf(alfa)
DK0934061T3 (da) Isobutylgaba og dets derivater til behandling af smerte
HK1156515A1 (en) Pharmaceutical compositions and methods for accelerating wound healing
BR0315597A (pt) Processos de baixa dose para tratamento de distúrbios em que a atividade de tnf(alfa)é prejudicial
BR9712824A (pt) Composição oftálmica de fator neurotrófico, agente de tratamento de desordem funcional do nervo ótico e método para tratamento de desordem funcional do nervo ótico
DK1604674T3 (da) Anvendelse af myoblaster til fremstilling af et medikament til behandling af stressinkontinens
BR9911887A (pt) Método para o tratamento da insÈnia
EA200501497A1 (ru) АМИНОКИСЛОТЫ С АФФИННОСТЬЮ К α2β-БЕЛКУ
ZA200107425B (en) Method for the treatment of incontinence.
IS5239A (is) Notkun á hliðstæðum gamma-amínósmjörsýru (GABA) áborð við GABA-pentín til vinnslu lyfs til meðferðar á bólgusjúkdómum
EA200501223A1 (ru) Терапевтическая система, содержащая амоксициллин и клавулановую кислоту
RS20060210A (en) Amino acids with affinity for the alpha2delta-protein
EP1621193A3 (en) Treatment of non-painful bladder disorders using alpha2-delta-subunit calcium channel modulators
PL345953A1 (en) The treatment of renal colic with gaba analogs
HN2003000108A (es) AMINOACIDOS CON AFINIDAD POR LA PROTEINA a2o´

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. A61K 31/195, 31/197; A61P 13/00

Ipc: A61K 31/195 (2011.01), A61K 31/197 (2011.01), A61P

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2144 DE 07/02/2012.